227 related articles for article (PubMed ID: 10360638)
1. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
Hospers GA; Eisenhauer EA; de Vries EG
Br J Cancer; 1999 May; 80(5-6):629-38. PubMed ID: 10360638
[TBL] [Abstract][Full Text] [Related]
2. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
3. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
4. Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
Batista CK; Mota JM; Souza ML; Leitão BT; Souza MH; Brito GA; Cunha FQ; Ribeiro RA
Cancer Chemother Pharmacol; 2007 Jan; 59(1):71-7. PubMed ID: 16708234
[TBL] [Abstract][Full Text] [Related]
5. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells.
Issels RD; Nagele A
Cancer Res; 1989 Apr; 49(8):2082-6. PubMed ID: 2539252
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
7. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL; Oster W
Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green D; Bensely D; Schein P
Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
[TBL] [Abstract][Full Text] [Related]
9. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
10. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
11. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
12. Amifostine: the first selective-target and broad-spectrum radioprotector.
Kouvaris JR; Kouloulias VE; Vlahos LJ
Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
14. [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon P; Petýrek P; Spurný V
Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
[TBL] [Abstract][Full Text] [Related]
15. Alternate delivery route for amifostine as a radio-/chemo-protecting agent.
Praetorius NP; Mandal TK
J Pharm Pharmacol; 2008 Jul; 60(7):809-15. PubMed ID: 18549666
[TBL] [Abstract][Full Text] [Related]
16. Amifostine: drug profile and nursing implications of the first pancytoprotectant.
Viele CS; Holmes BC
Oncol Nurs Forum; 1998 Apr; 25(3):515-23. PubMed ID: 9568606
[TBL] [Abstract][Full Text] [Related]
17. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
18. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
19. Cytoprotective effects of amifostine in the treatment of childhood malignancies.
Cetingül N; Midyat L; Kantar M; Demirağ B; Aksoylar S; Kansoy S
Pediatr Blood Cancer; 2009 Jul; 52(7):829-33. PubMed ID: 19214974
[TBL] [Abstract][Full Text] [Related]
20. Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
Mangoni M; Yue X; Morin C; Violot D; Frascogna V; Tao Y; Opolon P; Castaing M; Auperin A; Biti G; Barritault D; Vozenin-Brotons MC; Deutsch E; Bourhis J
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1242-50. PubMed ID: 19545790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]